INCY – Market expectations are for Uniform ROA compression, but management is confident about Monjuvi, Jakafi sales, and their LIMBER program

July 13, 2021

  • Incyte Corporation (INCY:USA) ccurrently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.7x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about Monjuvi combinations, Jakafi sales growth, and their LIMBER program.
  • Specifically, management is confident they are initiating a small trial to test their BET inhibitor and ruxolitinib combination safety and that the LIMBER program may pursue fixed-dose combinations for once-daily products. In addition, they are confident updated Monjuvi and LEN combination follow-up results continues to improve and that higher patient demand drove Jakafi net product sales growth.

You don’t have access to the Valens Research Premium Application.

To get access to our best content including the highly regarded Conviction Long List and Market Phase Cycle macro newsletter, please contact our Client Relations Team at 630-841-0683 or email

Please fill out the fields below so that our client relations team can contact you

Or contact our Client Relationship Team at 630-841-0683